Scholar4AI Updated 2026-10-31 19:11 UTC+09:00

Bristol-Myers Squibb (United Kingdom)

Papers in the tracked journals with an author at Bristol-Myers Squibb (United Kingdom): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education. Also as Markdown.

Share: X LinkedIn Bluesky Threads Facebook Reddit Hacker News Hatena LINE Email
Copy:

← Corporate research

Key findings#

  • From 2017 to 2026 (so far), authors at Bristol-Myers Squibb (United Kingdom) took part in 30 papers in the tracked journals, most of them in health economics and policy (29) and statistics (1).
  • 3 of them were published in 2025, against 2 in 2017.
  • Since 2023, the institutions with the most of these papers were Bristol-Myers Squibb (United States) (12), Bristol-Myers Squibb (France) (2) and University College London (2).
  • The journals publishing most of them were PharmacoEconomics - Open (9), PharmacoEconomics (3) and The European Journal of Health Economics (2).
  • The most-cited of them is “Artificial Intelligence to Automate Network Meta-Analyses: Four Case Studies to Evaluate the Potential Application of Large Language Models” (PharmacoEconomics - Open, 2024), with 71 citations.

Papers per year#

2017: 2 papers2018: 4 papers2019: 3 papers2020: 1 paper2021: 3 papers2022: 2 papers2023: 3 papers2024: 8 papers2025: 3 papers2026 (so far): 1 paper
20172026 (so far)
Papers per publication year and category
Category2017201820192020202120222023202420252026 (so far)
Health Economics and Policy2431323731
Statistics0000000100
All categories2431323831

Where the papers come from#

Institutions with the most papers, since 2023
#InstitutionPapers
1Bristol-Myers Squibb (United States)12
2Bristol-Myers Squibb (France)2
3University College London2
4University of Glasgow2
5University of Sheffield2
6Adelphi Group (United Kingdom)1
7Bristol-Myers Squibb (Sweden)1
8Bristol-Myers Squibb (Switzerland)1
9Centre National de la Recherche Scientifique1
Countries with the most papers, since 2023
#CountryPapers
1United Kingdom15
2United States12
3France2
4Switzerland1
5China1
6Denmark1
7Sweden1
Keywords with the most papers, since 2023
#KeywordPapers
1cost-effectiveness6
2quality-adjusted life years5
3health care costs3
4health technology assessment3
5immune checkpoint inhibitors3
6large language models3
7nivolumab3
8GPT-42
9atrial fibrillation2
10cancer immunotherapy2

Most-cited papers#

Most-cited papers since 2017
#CitationsPer monthTitleJournalPublishedAuthors
1712.2Artificial Intelligence to Automate Network Meta-Analyses: Four Case Studies to Evaluate the Potential Application of Large Language ModelsPharmacoEconomics - Open2024-02-10Tim Reason, Emma Benbow, Julia Langham et al.
2650.6Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and ExtrapolationPharmacoEconomics2017-09-02Eddie Gibson, Ian Koblbauer, Najida Begum et al.
3411.3Artificial Intelligence to Automate Health Economic Modelling: A Case Study to Evaluate the Potential Application of Large Language ModelsPharmacoEconomics - Open2024-02-10Tim Reason, William D. Rawlinson, Julia Langham et al.
4320.3The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in EnglandThe European Journal of Health Economics2018-03-09Yang Meng, Nadine Hertel, J. Ellis et al.
5270.3An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?Health Policy2018-04-26Jason T. Shafrin, Michelle Skornicki, Michelle Brauer et al.
6270.4What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell CarcinomaPharmacoEconomics2021-01-11Sven L. Klijn, Elisabeth A. L. Fenwick, Sonja Kroep et al.
7240.3Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in EnglandPharmacoEconomics - Open2020-12-17Ben Rothwell, Christopher Kiff, Caroline S. Ling et al.
8210.3A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data MaturityPharmacoEconomics2019-12-17Tim S. Grant, Darren K. Burns, Christopher Kiff et al.
9200.2Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in EnglandPharmacoEconomics - Open2018-05-22Dawn Lee, A. Amadi, Javier Sabater et al.
10191.1Using Generative Artificial Intelligence in Health Economics and Outcomes Research: A Primer on Techniques and BreakthroughsPharmacoEconomics - Open2025-04-29Tim Reason, Sven L. Klijn, William D. Rawlinson et al.
Cite this page

Scholar4AI. (2026). Bristol-Myers Squibb (United Kingdom). Journal Research Rankings. Retrieved October 31, 2026, from https://scholar4ai.com/companies/bristol-myers-squibb-united-kingdom

@misc{scholar4ai-companies-bristol-myers-squibb-united-kingdom,
  author = {{Scholar4AI}},
  title = {Bristol-Myers Squibb (United Kingdom)},
  year = {2026},
  howpublished = {\url{https://scholar4ai.com/companies/bristol-myers-squibb-united-kingdom}},
  urldate = {2026-10-31},
  note = {Journal Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}

Free to reuse for non-commercial purposes with attribution (CC BY-NC 4.0).